Free shipping starts now, no minimum, no coupons required!


A Potent and Selective Antagonist of NMDA Receptors

Cat #: C-325
Lyophilized Powder yes
  • Bioassay Tested
  • Source Synthetic
    MW: 209.14
    Purity: >98%
    Effective concentration 10-100 nM.
    Chemical name (E)-2-amino-4-methyl-5-phosphonopent-3-enoic acid.
    Molecular formula C6H12NO5P.
    CAS No.: 127910-31-0
    PubChem CID 5950212
    Activity CGP-37849 is a potent and selective antagonist of NMDA receptors, inhibiting the binding of selective NMDA ligand [3H]-CPP to rat brain NMDA with Ki of 35 nM. Orally bioavailable anticonvulsant in vivo1.
    1. Fagg, G.E. et al. (1990) Br. J. Pharmacol. 99, 791.
    Shipping and storage Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at +4°C.
    Solubility Up to 50 mM in water. May require gentle warming. Centrifuge all product preparations before use (10000 x g 5 min).
    Storage of solutions Store at -20°C. It is recommended to prepare solutions afresh on the day of use, or aliquot stock solutions stored at -20°C to prevent repeated thawing.
    Our bioassay
    • Alomone Labs CGP-37849 inhibits NMDA receptor channels expressed in Xenopus oocytes.
      Alomone Labs CGP-37849 inhibits NMDA receptor channels expressed in Xenopus oocytes.
      A. Representative time course of NR1/NR2A currents, elicited by transient stimulations with 50 µM glutamate + 50 µM glycine every 50 sec, while membrane potential was held at -60 mV. 4 min applications of 5 nM and 25 nM CGP-37849 (#C-325) reversibly inhibits current amplitude. B. Superimposed current traces from the recording shown in A, upon application of control, 5 nM and 25 nM CGP-37849 (as indicated).
    References - Scientific background
    1. Fagg, G.E. et al. (1990) Br. J. Pharmacol. 99, 791.
    2. Black, S.A. et al. (2014) Front. Cell Dev. Biol. 2, 45.
    Scientific background

    CGP-37849 is a synthetic compound that acts as a potent, selective, and competitive antagonist of N-methyl-d-aspartate (NMDA) receptors. CGP 37849 shows significant central effects following oral administration to animals. CGP-37849 is used to elucidate the roles of NMDA receptors in brain function, and as therapeutic agents for the treatment of neurological disorders such as epilepsy and ischemic brain damage in humans1.

    NMDA receptors are heterotetrameric channels formed by the assembly of two obligatory GluN1 and two GluN2/GluN3 subunits. They play important roles in a variety of cellular processes and brain functions such as synaptic plasticity, addiction, and stroke. NMDA receptors mediate physiological functions such as learning and memory formation and participate in glutamate excitotoxicity2.

    Target NMDA receptors
    Last update: 06/11/2022

    CGP-37849 (#C-325) is a highly pure, synthetic, and biologically active compound.

    For research purposes only, not for human use
    Shipping and Ordering information